- Presentation with live webcast Thursday, May 5 at 3:30 p.m. ET -
- Presentation to include Company's recent acquisition of Interactive Motion Technologies, Inc. -
TORONTO and BOSTON, May 2, 2016 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQX: BNKL), a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders ("Bionik" or the "Company"), announced today that Peter Bloch, Chief Executive Officer and Chairman of the Board will present at the inaugural Pioneers 2016 presented by Joseph Gunnar & Co., LLC conference on Thursday, May 5, 2016 at 3:30 p.m. ET in New York, NY.
Mr. Bloch will provide a corporate update and will discuss Bionik's recent acquisition of Interactive Motion Technologies, Inc. ("IMT"), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic tools for neurorehabilitation.
Through the acquisition of IMT, Bionik's product line now includes three upper extremity clinical rehabilitation products currently on the market for clinical use and two lower-body robots available for research use, being developed for clinical release. In addition the Company now has a potential pipeline to other new product candidates based on recent research being done at Massachusetts Institute of Technology ("MIT") by Hermano I. Krebs, Ph.D., M.S., Chief Science Officer of Bionik and Dr. Neville Hogan, who now serves as an advisor to the Bionik team. The clinical products have been characterized as Class II medical devices by the U.S. Food and Drug Administration ("FDA") and are currently sold in over 20 countries, including the United States. In addition, Bionik will maintain IMT's U.S. manufacturing facility based in Boston, Massachusetts, which is compliant with ISO-13485 and FDA regulations.
A live webcast of the presentation will be available on Bionik's IR Calendar in the Investor Relations section of the Company's website (www.bioniklabs.com). The webcast replay will be available for approximately two hours after the presentation ends and will be archived for 30 days.
About Pioneers 2016
The Pioneers Conference is dedicated to providing a forum where publicly traded companies can network with the investment community. The 2016 Conference will feature presentations by CEOs and CFOs from several principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis.
About Bionik Laboratories
Bionik Laboratories (OTCQX: BNKL), is a global, pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders. Through the acquisition of Interactive Motion Technologies, Bionik has added a portfolio of products focused on upper and lower extremity rehabilitation of stroke patients. The Company now has three products on the market and three products in varying stages of development. The InMotion Systems - the InMotion ARM™, InMotionWrist™, InMotion Hand™ and InMotion Ankle™, are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. Each of Bionik's products are or are expected to be designed to continually adapt to a patient's ability and provide real time feedback to the physiotherapist through the use of Bionik's proprietary data collection and analytics cloud network through its partnership with IBM.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the successful integration of IMT with Bionik and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bionik-laboratories-to-present-at-the-joseph-gunnar--co-llc-pioneers-2016-conference-300260591.html
SOURCE Bionik Laboratories Corp.